Endocyte Inc (ECYT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
52
About the Report
About the Report
Summary
Endocyte Inc (Endocyte) is a biopharmaceutical company that develops targeted therapies for the treatment of cancer and inflammatory diseases. The company's pipeline products include Lu-PSMA-617 and Ac-PSMA-617 for radiologand therapy, and FITC CAR-T. Endocyte's proprietary small molecule drug conjugate (SMDC) technology is used to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company develops therapeutic immunotherapy approach that involves potent immune cells, called chimeric antigen receptor T-cell (CAR T-cell) to fight cancer. It has operations in Indianapolis and West Lafayette. Endocyte is headquartered in West Lafayette, Indiana, the US.
Endocyte Inc (ECYT)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Endocyte Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Endocyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Endocyte Inc, Medical Devices Deals, 2012 to YTD 2018 10
Endocyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Endocyte Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Kyzeo Imaging Enters into Agreement with Endocyte 12
Endocyte Enters into Agreement Seattle Children's Research Institute 13
Licensing Agreements 14
Endocyte Receives Rights from Radiomedix 14
Endocyte Enters into Licensing Agreement with ABX 15
Endocyte Enters into Licensing Agreement with Nihon Medi-Physics for Etarfolatide 16
Equity Offering 17
Endocyte Raises USD201.2 Million in Public Offering of Shares 17
Endocyte Raises USD86.3 Million in Public Offering of Shares 18
Endocyte Plans to Raise up to USD150 Million in Public Offering of Securities 19
Endocyte Raises Funds through Private Placement of Shares and Warrants 20
Endocyte Raises USD4.5 Million in Private Placement of Shares upon Exercise of Warrants 21
Endocyte Completes Public Offering Of Shares For USD 108.7 Million 22
Acquisition 23
Novartis to Acquire Endocyte 23
Endocyte Inc-Key Competitors 25
Endocyte Inc-Key Employees 26
Endocyte Inc-Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Recent Developments 28
Financial Announcements 28
Jul 31, 2018: Endocyte provides second quarter 2018 financial results and operational update 28
May 09, 2018: Endocyte Provides First Quarter 2018 Financial Results and Operational Update 30
Nov 06, 2017: Endocyte Reports Third Quarter Financial Results 32
Aug 08, 2017: Endocyte Reports Second Quarter Financial Results and Provides Clinical and Pipeline Update 34
May 10, 2017: Endocyte Reports First Quarter Financial Results and Provides Clinical and Pipeline Update 36
Mar 10, 2017: Endocyte Reports Fourth Quarter and Year End 2016 Financial Results and Provides Clinical and Pipeline Update 38
Corporate Communications 40
Mar 15, 2018: Endocyte Nominates Dawn Svoronos for Election to Its Board of Directors and Announces Other Board Developments 40
Feb 27, 2018: Endocyte Appoints Patrick Machado, J.D. to Its Board of Directors 41
Feb 21, 2017: Endocyte Appoints Michael T. Andriole as Chief Financial Officer 42
Product News 43
10/17/2017: New Potential Treatment for Prostate Cancer Receives Boost 43
09/06/2017: Endocyte Presents Data at the 2017 CAR-TCR Summit Further Demonstrating the Ability to Manage Cytokine Release Syndrome Related to CAR T-Cell Therapy 44
04/16/2018: Endocyte Presents Data from its CAR T Platform at American Association for Cancer Research (AACR) Annual Meeting 2018 45
Clinical Trials 46
Sep 05, 2017: Endocyte Announces Presentation at the European Society for Medical Oncology 46
Jun 02, 2017: Endocyte Announces Clinical Update for EC1169 47
May 26, 2017: Endocyte to Announce Updated Data on clinical-stage asset EC1169 at the 2017 American Society of Clinical Oncology Annual Meeting 48
Other Significant Developments 49
Oct 03, 2018: Endocyte becomes first Purdue startup to reach USD 1.5B in value 49
Appendix 52
Methodology 52
About GlobalData 52
Contact Us 52
Disclaimer 52
List of Figure
List of Figures
Endocyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Endocyte Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Endocyte Inc, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Endocyte Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Endocyte Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Endocyte Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Endocyte Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Endocyte Inc, Medical Devices Deals, 2012 to YTD 2018 10
Endocyte Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Kyzeo Imaging Enters into Agreement with Endocyte 12
Endocyte Enters into Agreement Seattle Children's Research Institute 13
Endocyte Receives Rights from Radiomedix 14
Endocyte Enters into Licensing Agreement with ABX 15
Endocyte Enters into Licensing Agreement with Nihon Medi-Physics for Etarfolatide 16
Endocyte Raises USD201.2 Million in Public Offering of Shares 17
Endocyte Raises USD86.3 Million in Public Offering of Shares 18
Endocyte Plans to Raise up to USD150 Million in Public Offering of Securities 19
Endocyte Raises Funds through Private Placement of Shares and Warrants 20
Endocyte Raises USD4.5 Million in Private Placement of Shares upon Exercise of Warrants 21
Endocyte Completes Public Offering Of Shares For USD 108.7 Million 22
Novartis to Acquire Endocyte 23
Endocyte Inc, Key Competitors 25
Endocyte Inc, Key Employees 26
Endocyte Inc, Other Locations 27
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.